<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p181" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_181{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_181{left:306px;bottom:30px;}
#t3_181{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_181{left:346px;bottom:30px;}
#t5_181{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_181{left:517px;bottom:30px;}
#t7_181{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_181{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_181{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_181{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_181{left:35px;bottom:777px;letter-spacing:0.03px;word-spacing:-0.15px;}
#tc_181{left:35px;bottom:754px;letter-spacing:0.08px;word-spacing:-0.85px;}
#td_181{left:35px;bottom:731px;letter-spacing:0.13px;word-spacing:0.06px;}
#te_181{left:35px;bottom:707px;letter-spacing:0.08px;word-spacing:0.11px;}
#tf_181{left:35px;bottom:684px;letter-spacing:0.11px;word-spacing:0.07px;}
#tg_181{left:35px;bottom:661px;letter-spacing:0.09px;word-spacing:0.1px;}
#th_181{left:35px;bottom:638px;letter-spacing:0.06px;word-spacing:0.12px;}
#ti_181{left:35px;bottom:614px;letter-spacing:0.01px;word-spacing:0.18px;}
#tj_181{left:264px;bottom:622px;letter-spacing:0.1px;}
#tk_181{left:309px;bottom:614px;letter-spacing:0.05px;word-spacing:0.14px;}
#tl_181{left:35px;bottom:591px;letter-spacing:0.18px;}
#tm_181{left:35px;bottom:568px;letter-spacing:0.07px;word-spacing:-1.11px;}
#tn_181{left:35px;bottom:545px;letter-spacing:0.06px;word-spacing:0.13px;}
#to_181{left:35px;bottom:522px;letter-spacing:0.1px;word-spacing:0.09px;}
#tp_181{left:35px;bottom:498px;letter-spacing:0.1px;word-spacing:0.09px;}
#tq_181{left:35px;bottom:475px;letter-spacing:0.05px;word-spacing:0.14px;}
#tr_181{left:35px;bottom:436px;letter-spacing:0.08px;word-spacing:0.11px;}
#ts_181{left:35px;bottom:413px;letter-spacing:0.12px;word-spacing:0.07px;}
#tt_181{left:35px;bottom:390px;letter-spacing:0.06px;word-spacing:0.12px;}
#tu_181{left:35px;bottom:366px;letter-spacing:0.05px;word-spacing:0.14px;}
#tv_181{left:35px;bottom:343px;letter-spacing:0.13px;word-spacing:0.05px;}
#tw_181{left:35px;bottom:320px;letter-spacing:0.12px;word-spacing:0.07px;}
#tx_181{left:35px;bottom:297px;letter-spacing:0.15px;word-spacing:0.04px;}
#ty_181{left:35px;bottom:273px;letter-spacing:0.04px;word-spacing:0.15px;}
#tz_181{left:35px;bottom:250px;letter-spacing:0.1px;word-spacing:0.09px;}
#t10_181{left:35px;bottom:227px;letter-spacing:0.08px;word-spacing:-0.22px;}
#t11_181{left:35px;bottom:204px;letter-spacing:0.25px;word-spacing:-0.06px;}
#t12_181{left:35px;bottom:162px;letter-spacing:0.18px;word-spacing:0.01px;}
#t13_181{left:35px;bottom:138px;letter-spacing:0.09px;word-spacing:0.1px;}
#t14_181{left:35px;bottom:116px;letter-spacing:-0.03px;word-spacing:0.22px;}
#t15_181{left:35px;bottom:93px;word-spacing:0.19px;}
#t16_181{left:35px;bottom:69px;letter-spacing:0.08px;word-spacing:0.11px;}
#t17_181{left:618px;bottom:777px;letter-spacing:0.1px;word-spacing:0.09px;}
#t18_181{left:618px;bottom:754px;letter-spacing:0.12px;word-spacing:0.07px;}
#t19_181{left:618px;bottom:731px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1a_181{left:618px;bottom:707px;letter-spacing:0.09px;word-spacing:-0.03px;}
#t1b_181{left:618px;bottom:684px;letter-spacing:0.1px;word-spacing:-0.59px;}
#t1c_181{left:618px;bottom:661px;letter-spacing:0.16px;word-spacing:-0.3px;}
#t1d_181{left:618px;bottom:638px;letter-spacing:0.01px;word-spacing:0.19px;}
#t1e_181{left:802px;bottom:645px;letter-spacing:0.1px;}
#t1f_181{left:847px;bottom:638px;letter-spacing:0.18px;}
#t1g_181{left:618px;bottom:614px;letter-spacing:0.15px;word-spacing:0.04px;}
#t1h_181{left:618px;bottom:591px;letter-spacing:0.18px;word-spacing:0.01px;}
#t1i_181{left:618px;bottom:568px;letter-spacing:0.09px;word-spacing:-0.1px;}
#t1j_181{left:618px;bottom:545px;letter-spacing:0.04px;word-spacing:-1.08px;}
#t1k_181{left:618px;bottom:522px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1l_181{left:618px;bottom:498px;letter-spacing:0.08px;word-spacing:0.1px;}
#t1m_181{left:618px;bottom:475px;letter-spacing:0.1px;word-spacing:-0.77px;}
#t1n_181{left:618px;bottom:452px;letter-spacing:0.13px;word-spacing:-0.25px;}
#t1o_181{left:618px;bottom:430px;letter-spacing:0.12px;word-spacing:0.06px;}
#t1p_181{left:618px;bottom:407px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1q_181{left:840px;bottom:414px;letter-spacing:0.12px;}
#t1r_181{left:929px;bottom:407px;letter-spacing:0.09px;word-spacing:0.09px;}
#t1s_181{left:618px;bottom:383px;letter-spacing:0.16px;word-spacing:0.02px;}
#t1t_181{left:618px;bottom:360px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1u_181{left:618px;bottom:337px;letter-spacing:0.03px;word-spacing:0.26px;}
#t1v_181{left:618px;bottom:314px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1w_181{left:618px;bottom:291px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1x_181{left:618px;bottom:267px;letter-spacing:-0.08px;word-spacing:0.27px;}
#t1y_181{left:618px;bottom:227px;letter-spacing:0.08px;word-spacing:0.11px;}
#t1z_181{left:1079px;bottom:235px;letter-spacing:0.1px;}
#t20_181{left:1124px;bottom:227px;letter-spacing:-0.31px;}
#t21_181{left:618px;bottom:204px;letter-spacing:0.2px;word-spacing:-0.01px;}
#t22_181{left:722px;bottom:211px;letter-spacing:-0.01px;}
#t23_181{left:746px;bottom:204px;letter-spacing:0.19px;}
#t24_181{left:618px;bottom:181px;letter-spacing:0.11px;word-spacing:0.08px;}
#t25_181{left:618px;bottom:157px;letter-spacing:0.03px;word-spacing:0.16px;}
#t26_181{left:618px;bottom:134px;letter-spacing:0.06px;}
#t27_181{left:739px;bottom:134px;letter-spacing:0.22px;word-spacing:-0.58px;}
#t28_181{left:618px;bottom:111px;letter-spacing:0.04px;word-spacing:0.15px;}
#t29_181{left:618px;bottom:88px;letter-spacing:0.08px;word-spacing:0.11px;}
#t2a_181{left:618px;bottom:64px;letter-spacing:0.09px;word-spacing:-0.45px;}
#t2b_181{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_181{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_181{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_181{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_181{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_181{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_181{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_181{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s7_181{font-size:17px;font-family:ArialMT_5tg;color:#005B99;}
.s8_181{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts181" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg181Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg181" style="-webkit-user-select: none;"><object width="1210" height="935" data="181/181.svg" type="image/svg+xml" id="pdf181" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_181" class="t s0_181">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_181" class="t s1_181">© </span>
<span id="t3_181" class="t s0_181">(NCCN </span>
<span id="t4_181" class="t s1_181">© </span>
<span id="t5_181" class="t s0_181">), All rights reserved. NCCN Guidelines </span>
<span id="t6_181" class="t s1_181">® </span>
<span id="t7_181" class="t s0_181">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_181" class="t s2_181">NCCN Guidelines Version 4.2024 </span>
<span id="t9_181" class="t s2_181">Head and Neck Cancers </span>
<span id="ta_181" class="t s3_181">MS-40 </span>
<span id="tb_181" class="t s4_181">induction chemotherapy sequence was also associated with better distant </span>
<span id="tc_181" class="t s4_181">control, compared to the adjuvant chemotherapy arm. However, this study </span>
<span id="td_181" class="t s4_181">was underpowered, due to the small number of patients in each study </span>
<span id="te_181" class="t s4_181">arm. Based upon the aggregate data, the NCCN Guidelines support the </span>
<span id="tf_181" class="t s4_181">use of induction over adjuvant chemotherapy in patients with </span>
<span id="tg_181" class="t s4_181">locoregionally advanced NPC. However, two trials have reported on the </span>
<span id="th_181" class="t s4_181">adjuvant use of capecitabine following standard chemoradiation of </span>
<span id="ti_181" class="t s4_181">locoregionally advanced NPC. </span>
<span id="tj_181" class="t s5_181">521,522 </span>
<span id="tk_181" class="t s4_181">One trial demonstrated PFS and OS </span>
<span id="tl_181" class="t s4_181">improvement from the use of 1 year of low-dose capecitabine following </span>
<span id="tm_181" class="t s4_181">definitive treatment, and the other demonstrated improvement in PFS. The </span>
<span id="tn_181" class="t s4_181">vast majority of patients treated on the low dose metronomic adjuvant </span>
<span id="to_181" class="t s4_181">capecitabine study had received both induction chemotherapy and </span>
<span id="tp_181" class="t s4_181">concurrent chemoradiation, supporting this adjuvant approach even in </span>
<span id="tq_181" class="t s4_181">patients heavily pretreated with sequential chemoradiation. </span>
<span id="tr_181" class="t s4_181">In summary, currently available evidence favors either the addition of </span>
<span id="ts_181" class="t s4_181">induction or adjuvant chemotherapy to concurrent systemic therapy/RT, </span>
<span id="tt_181" class="t s4_181">compared to systemic therapy/RT alone, in patients with locoregionally </span>
<span id="tu_181" class="t s4_181">advanced NPC. Evidence suggests that induction chemotherapy may be </span>
<span id="tv_181" class="t s4_181">associated with a greater benefit for distant progression, and this is the </span>
<span id="tw_181" class="t s4_181">preferred approach in the NCCN Guidelines for locally advanced NPC. </span>
<span id="tx_181" class="t s4_181">The routine use of adjuvant capecitabine following either induction and </span>
<span id="ty_181" class="t s4_181">chemoradiation or chemoradiation alone is less established. Due to </span>
<span id="tz_181" class="t s4_181">concerns about escalating toxicity, ongoing investigations continue with </span>
<span id="t10_181" class="t s4_181">the goal of more precisely delineating which classes of NPC patients may </span>
<span id="t11_181" class="t s4_181">be safely offered lesser-intensity regimens. </span>
<span id="t12_181" class="t s6_181">NCCN Recommendations </span>
<span id="t13_181" class="t s4_181">Patients with an unknown primary site after appropriate workup but </span>
<span id="t14_181" class="t s4_181">harboring cervical lymph nodal squamous cell carcinoma that is EBV- </span>
<span id="t15_181" class="t s4_181">positive may be treated in the same manner as locoregionally advanced </span>
<span id="t16_181" class="t s4_181">NPC. For other EBV-associated NPC, the principles of treatment can </span>
<span id="t17_181" class="t s4_181">mostly be outlined according to stage. Patients with T1, N0, M0 </span>
<span id="t18_181" class="t s4_181">nasopharyngeal tumors should be treated with definitive RT alone, </span>
<span id="t19_181" class="t s4_181">including elective RT to the neck. Since T2, N0 disease is less likely to </span>
<span id="t1a_181" class="t s4_181">progress to distant metastasis compared to T2, N1 disease, definitive RT </span>
<span id="t1b_181" class="t s4_181">alone could be used; concurrent systemic therapy may be indicated in the </span>
<span id="t1c_181" class="t s4_181">presence of high-risk features such as bulky tumor volume or high serum </span>
<span id="t1d_181" class="t s4_181">EBV DNA copy number. </span>
<span id="t1e_181" class="t s5_181">523,524 </span>
<span id="t1f_181" class="t s4_181">Induction chemotherapy followed by </span>
<span id="t1g_181" class="t s4_181">systemic therapy/RT is preferred for advanced locoregional disease (ie, </span>
<span id="t1h_181" class="t s4_181">T3–4, N1-N3 or any T, N2–3 disease). For patients who did not receive </span>
<span id="t1i_181" class="t s4_181">induction chemotherapy, adjuvant chemotherapy following treatment with </span>
<span id="t1j_181" class="t s4_181">concurrent systemic therapy/RT is recommended. The use of capecitabine </span>
<span id="t1k_181" class="t s4_181">as adjuvant treatment following induction and concurrent chemoradiation </span>
<span id="t1l_181" class="t s4_181">is supported by two randomized clinical trials. Concurrent systemic </span>
<span id="t1m_181" class="t s4_181">therapy/RT alone is recommended for patients with T0–2, N1 disease and </span>
<span id="t1n_181" class="t s4_181">can be considered for select patients with lower risk T3, N0 disease, who </span>
<span id="t1o_181" class="t s4_181">were excluded from randomized trials evaluating the benefits of adjuvant </span>
<span id="t1p_181" class="t s4_181">and induction chemotherapy. </span>
<span id="t1q_181" class="t s5_181">504,511,512,525 </span>
<span id="t1r_181" class="t s4_181">Induction or adjuvant </span>
<span id="t1s_181" class="t s4_181">chemotherapy may be considered for these patients in the presence of </span>
<span id="t1t_181" class="t s4_181">high-risk features, including, for example, a high EBV DNA titer, which </span>
<span id="t1u_181" class="t s4_181">may indicate worse prognosis. For NPC that is not virally driven, similar </span>
<span id="t1v_181" class="t s4_181">principles are applied, although it may be a consideration that these </span>
<span id="t1w_181" class="t s4_181">tumors are generally more prone to local relapse and have lower rates of </span>
<span id="t1x_181" class="t s4_181">distant metastases. </span>
<span id="t1y_181" class="t s4_181">When induction chemotherapy is used, gemcitabine/cisplatin </span>
<span id="t1z_181" class="t s5_181">512,526 </span>
<span id="t20_181" class="t s4_181">and </span>
<span id="t21_181" class="t s4_181">modified TPF </span>
<span id="t22_181" class="t s5_181">525 </span>
<span id="t23_181" class="t s4_181">are both preferred options for patients with EBV-related </span>
<span id="t24_181" class="t s4_181">NPC. Other induction/sequential chemotherapy regimens are included in </span>
<span id="t25_181" class="t s4_181">the NCCN Guidelines for Head and Neck Cancers (available at </span>
<span id="t26_181" class="t s7_181">www.NCCN.org</span><span id="t27_181" class="t s4_181">) based on lower-level evidence. The use of induction for </span>
<span id="t28_181" class="t s4_181">patients with non–EBV-related NPC remains undefined, as all trials </span>
<span id="t29_181" class="t s4_181">studying induction in NPC were in EBV-related NPC patient populations. </span>
<span id="t2a_181" class="t s4_181">When using induction chemotherapy for non–EBV-related NPC, it may be </span>
<span id="t2b_181" class="t s8_181">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
